COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00051688
Recruitment Status : Terminated
First Posted : January 16, 2003
Last Update Posted : July 11, 2006
Information provided by:
Chiron Corporation

Brief Summary:
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Drug: tezacitabine Drug: oxaliplatin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Study Start Date : June 2003
Study Completion Date : August 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy.
  • Patients must have at least one measurable tumor.
  • Patients may not have received prior treatment with oxaliplatin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00051688

Layout table for location information
United States, Arizona
ACRC/Arizona Clinical Research Center
Tucson, Arizona, United States, 85712
United States, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States, 92262
Cancer Institute Medical Group
Santa Monica, California, United States, 90404
United States, District of Columbia
Georgetown University Medical Center, Lombardi Cancer Center
Washington, District of Columbia, United States, 20007
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612-9497
United States, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60611
United States, Missouri
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States, 64111
Sponsors and Collaborators
Chiron Corporation
Layout table for additonal information Identifier: NCT00051688    
Other Study ID Numbers: TEZ101
First Posted: January 16, 2003    Key Record Dates
Last Update Posted: July 11, 2006
Last Verified: July 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action